Pancreatic Cancer Research

ResearcherEdinburgh Cancer ResearchActive in the last 2 years

Alan Serrels

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4992-6077; OpenAlex author ID A5001264667. Sources: OpenAlex.

Their work

Papers
4 (first author 0, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
5
Papers, trials and grants by year

2017: 1 paper · 2018: none · 2019: none · 2020: none · 2021: none · 2022: 1 paper · 2023: 1 paper · 2024: none · 2025: 1 paper

Papers 4

  1. Tumour genotype shapes blood biomarker expression for use in pancreatic cancer detection and diagnosis Last author DOI 10.1101/2025.08.15.670486↗
  2. FAK suppresses antigen processing and presentation to promote immune evasion in pancreatic cancer. Last author DOI 10.1136/gutjnl-2022-327927↗
  3. FAK promotes stromal PD-L2 expression associated with poor survival in pancreatic cancer. Last author DOI 10.1038/s41416-022-01966-5↗
  4. FAK-inhibition opens the door to checkpoint immunotherapy in Pancreatic Cancer. Last author DOI 10.1186/s40425-017-0217-6↗

Closest collaborators

The 5 strongest of 5 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Marta Canel · 3 shared papers, 2022–2025 · strength 0.64
  2. Catherine Davidson · 2 shared papers, 2022–2023 · strength 0.36
  3. Jennifer P. Morton · 1 shared paper, 2025 · strength 0.28
  4. Andrew Victor Biankin · 1 shared paper, 2023 · strength 0.17
  5. Stefan Nicholas Symeonides · 1 shared paper, 2017 · strength 0.12

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.